Docetaxel and/or Zoledronic Acid for Hormone Naïve Prostate Cancer Abstract #5001 ASCO 2015

First results of STAMPEDE trial


1. Docetaxel, added to standard hormonal therapy, improved overall survival by median of 10 months with hormone naive, newly diagnosed individuals with advanced prostate cancer. PI of the study Nicholas James MD, PhD of the University of Warwick and Queen Elizabeth Hospital, Birmingham, England

2. "Docetaxel improved survival in patients with newly diagnosed metastatic prostate cancer starting hormones, and it should be routinely used in these patients as part of upfront therapy. In non-metastatic disease, docetaxel should be offered to men about to start hormone therapy for the first time, because it prolongs failure-free survival. There is some uncertainty regarding its effect on overall survival in men with non-metastatic disease, and longer follow-up is needed. It’s clear that zaledronic acid does not benefit patients with advanced prostate cancer and should not be offered as upfront treatment" (ASCO POST, May 25, 2015 page 1)

3. STAMPEDE is the largest randomized trial conducted for treatment of prostate cancer

4. Comment: represents major change in standard of care for newly diagnosed prostate cancer patients presenting with advanced disease

Please don't hesitate to contact Dr. Steven Mamus to discuss this topic. 

09 June 2015, 02:31
Add comment

Comments (0)